Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 28, 2021 - AbbVie announced the FDA approval of Qulipta (atogepant), for the preventive treatment of episodic migraine in adults.
Download PDF
Return to publications
